First Quadrant’s PDL BioPharma, Inc. PDLI Stock Holding History

First Quadrant’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,813	Closed	-$23K	–	909
2018 Q2	$23K	Buy	+9,813	New	+$27.4K	﹤0.01%	741
2018 Q1	–	Sell	-16,267	Closed	-$45K	–	993
2017 Q4	$45K	Buy	16,267 +7,167	+79%	+$22K	﹤0.01%	854
2017 Q3	$31K	Buy	+9,100	New	+$25.3K	﹤0.01%	870
2017 Q1	–	Sell	-259,833	Closed	-$551K	–	885
2016 Q4	$551K	Sell	259,833 -142,113	-35%	-$397K	0.01%	525
2016 Q3	$1.35M	Buy	401,946 +230,346	+134%	+$731K	0.03%	398
2016 Q2	$539K	Buy	171,600 +151,900	+771%	+$507K	0.01%	479
2016 Q1	$66K	Buy	+19,700	New	+$61.4K	﹤0.01%	669
2015 Q4	–	Sell	-38,000	Closed	-$191K	–	886
2015 Q3	$191K	Buy	+38,000	New	+$218K	﹤0.01%	547
2014 Q3	–	Sell	-67,700	Closed	-$655K	–	870
2014 Q2	$655K	Sell	67,700 -175,200	-72%	-$1.56M	0.01%	440
2014 Q1	$2.02M	Sell	242,900 -10,200	-4%	-$87.4K	0.05%	304
2013 Q4	$2.14M	Hold	253,100	–	–	0.05%	311
2013 Q3	$2.02M	Buy	253,100 +8,800	+4%	+$70.7K	0.05%	291
2013 Q2	$1.89M	Buy	+244,300	New	+$1.9M	0.05%	293

Other funds holding PDLI

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

First Quadrant's PDLI Position: Q3 2018 in Review

First Quadrant sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 9,813 shares — an estimated $23K sold.

First Quadrant first reported a position in PDLI in Q2 2013 and held it in 13 quarters. The position peaked at $2.14M in Q4 2013. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

First Quadrant reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
First Quadrant sold 9,813 PDL BioPharma, Inc. shares in Q3 2018, an estimated $23K.
First Quadrant first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 13 quarters.
First Quadrant's PDL BioPharma, Inc. position peaked at $2.14M in Q4 2013.
152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on First Quadrant's 13F filing for Q3 2018, filed 23 Oct 2018.